TY - JOUR
T1 - Cerebrospinal fluid biomarkers for Alzheimer's disease
T2 - The present and the future
AU - Ghidoni, Roberta
AU - Benussi, Luisa
AU - Paterlini, Anna
AU - Albertini, Valentina
AU - Binetti, Giuliano
AU - Emanuele, Enzo
PY - 2011/7
Y1 - 2011/7
N2 - Alzheimer's disease (AD) is the major cause of dementia in the elderly. The biochemical changes that precede AD may be present up to 20 years before the clinical manifestation of the disease. The translational development of AD biomarkers may be theoretically achieved via two different strategies: the first strategy can be defined as 'knowledge-based' (deductive method), while the second one is a hypothesis-generating 'unbiased' approach (inductive strategy). The 'knowledge-based' approach relies on a direct understanding of the neuropathological processes that underlie the development of AD. In contrast, the 'unbiased' approach involves the use of modern techniques including proteomics and bioinformatics that allow unbiased investigations of numerous putative markers that may be informative with regard to AD. Cerebrospinal fluid (CSF) dosage of neuropathological AD-associated proteins has already been incorporated into the neurochemical diagnosis of AD, attesting the relevance of translational research. In the last few years, biomarker discovery research has successfully utilized genomics and proteomics for the identification of several promising molecular markers for AD. In the present article, we discuss the present state of the art and the future challenges in the search of CSF biomarkers for AD.
AB - Alzheimer's disease (AD) is the major cause of dementia in the elderly. The biochemical changes that precede AD may be present up to 20 years before the clinical manifestation of the disease. The translational development of AD biomarkers may be theoretically achieved via two different strategies: the first strategy can be defined as 'knowledge-based' (deductive method), while the second one is a hypothesis-generating 'unbiased' approach (inductive strategy). The 'knowledge-based' approach relies on a direct understanding of the neuropathological processes that underlie the development of AD. In contrast, the 'unbiased' approach involves the use of modern techniques including proteomics and bioinformatics that allow unbiased investigations of numerous putative markers that may be informative with regard to AD. Cerebrospinal fluid (CSF) dosage of neuropathological AD-associated proteins has already been incorporated into the neurochemical diagnosis of AD, attesting the relevance of translational research. In the last few years, biomarker discovery research has successfully utilized genomics and proteomics for the identification of several promising molecular markers for AD. In the present article, we discuss the present state of the art and the future challenges in the search of CSF biomarkers for AD.
KW - Alzheimer's disease
KW - Biomarker
KW - Cerebrospinal fluid
KW - Proteomics
KW - Translational research
UR - http://www.scopus.com/inward/record.url?scp=79960555311&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960555311&partnerID=8YFLogxK
U2 - 10.1159/000327756
DO - 10.1159/000327756
M3 - Article
C2 - 21709402
AN - SCOPUS:79960555311
VL - 8
SP - 413
EP - 420
JO - Neurodegenerative Diseases
JF - Neurodegenerative Diseases
SN - 1660-2854
IS - 6
ER -